Program Book - Confex

More documents

Recommendations

Info

Invited Speaker /Moderator Index Omega-3 Fatty Acids in Inflammation and Cardiovascular Health. . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Ruffing, Victoria L., RN Fiscal Management of Infusion Clinics: Academic and Private Practice Perspectives . . . . . . 93 Disclosure: Nothing to Disclose Russell, R. Graham G., MD, PhD, FRS Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Amgen, Lilly, Novartis, GSK, Roche, Warner Chilcott, 5; Warner Chilcott, 2 S Saag, Kenneth G., MD, MSc 2011 Updated ACR Rheumatoid Arthritis Guidelines . . . . . . . . . . . . . . . . . . . 63 Disclosure: Amgen, 2, 5; Eli Lilly and Company, 2, 5; Genentech and Biogen IDEC Inc., 5; Horizon, 5; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Proctor Gamble, 2; Sanofi Aventis, 2; Takeda, 2; URL, 5 Great Debate: Is too Much Suppression of Turnover Bad for Bone. . . . . . . . . . . . 42 Disclosure: Amgen, 2, 5; Eli Lilly and Company, 2, 5; Genentech and Biogen IDEC Inc., 5; Horizon, 5; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Proctor Gamble, 2; Sanofi Aventis, 2; Takeda, 2; URL, 5 Salmon, Jane E., MD Mechanisms of Thrombosis in Systemic Autoimmune Disease . . . . . . . . . . . . 117 Disclosure: Nothing to Disclose Salt, Elizabeth G., PhD Antimalarials for Rheumatic Disorders: Historical Perspectives, Clinical Insights and Future Directions . . . . . . . . . . . . . . . . . . . 57 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Behave Yourself! Practical Application of Cognitive Behavioral Theories to Motivate Change in Patients with Arthritis. . . . . . . 54 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Best Practices for Collaboration in Research and Clinical Practice . . . . . . . . . . . . . . . . 31 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Daltroy Memorial Lecture: The Role of Cultural Diversity in Patient-Healthcare Provider Communication . . . . . . . . . . . . . . . . 89 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Improving Adherence in the Pediatric Patient . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Pain: Pathophysiology and Clinical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . 24 Disclosure: SmithKline Beecham, 1; Research and Education Foundation, 2 Sammaritano, Lisa R., MD Management of Antiphospholipid Syndrome- From Controversies to Consensus . . . . . . 45 Disclosure: Nothing to Disclose Sanchez-Guerrero, Jorge, MD, MS Systemic Lupus Erythematosus: Central Nervous System . . . . . . . . . . . . . . . . . . . . . 51 Disclosure: Nothing to Disclose Sawalha, Amr H., MD Theories on Sex Disparities in Autoimmune Disease: From Estrogen to the X Chromosome . . . . . . . . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Scalapino, Kenneth J., MD Rheumatic Disease Update: Musculoskeletal Manifestiations of Human Immunodeficiency Virus . . . . . . . . . . . . . . . . . . . . . . 58 Disclosure: Nothing to Disclose Scanzello, Carla R., MD, PhD Osteoarthritis: A Disease of the Joint as an Organ . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: Nothing to Disclose Schanberg, Laura E., MD Complex Pain Issues: Comorbidities and Special Populations . . . . . . . . . . . . . . . . . . 24 Disclosure: AstraZeneca, 5; GlaxoSmithKline, 5; Pfizer Inc, 2; UCB, 5 Session IV: Successes in Rheumatology Comparative Effectiveness Research. . . . . 22 Disclosure: Nothing to Disclose Scher, Jose U., MD T-Cell Regulation and Autoimmune Pathogenesis: Th1, Th2, Th17 and T Regs . . 54 Disclosure: Nothing to Disclose Schett, Georg, MD, PhD Pain Pathways in Rheumatic Diseases . . . .125 Disclosure: Nothing to Disclose Session I: Ontogeny and Regulation of Bone Cells . . . . . . . . . . . . . . . . . . . . . . 18 Disclosure: Nothing to Disclose Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 20 Disclosure: Nothing to Disclose Session IV: Assessment of Bone Structure and Quality . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Nothing to Disclose Schikler, Kenneth N., MD Periodic Fevers with Aphthous Stomatitis, Pharyngitis, and Adenitis . . . . . . . . . . . 91 Disclosure: Nothing to Disclose The Child with Chronic Pain . . . . . . . . .108 Disclosure: Pfizer Inc, Forest Labs, 2 Schlesinger, Naomi, MD Crystal: Diagnosis and Management of Gout . . . . . . . . . . . . . . . . . . . . . . . . . . 51 Disclosure: Advisory boards: Novartis ,Savient, URL Pharma, EnzymeRx , 5; NJ Rheumatology association, 9; Novartis Pharmaceutical Corporation, 2; Savient, Takeda, Novartis, 8 Schmidt, Wolfgang A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day One. . . . . . . . . . 17 Disclosure: Abbott Immunology Pharmaceuticals, 8; Actelion Pharmaceuticals US, 2; Berlin Chemie, 8; Bristol-Myers Squibb, 8; Chugai, 8; Esaote, 2; Medac, 8; Merck Pharmaceuticals, 8; Merck Sharp Dome, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 8; Roche Pharmaceuticals, 8 Musculoskeletal Ultrasound Course for Rheumatologists - Day Two. . . . . . . . . . 20 Disclosure: Abbott Immunology Pharmaceuticals, 8; Actelion Pharmaceuticals US, 2; Berlin Chemie, 8; Bristol-Myers Squibb, 8; Chugai, 8; Esaote, 2; Medac, 8; Merck Pharmaceuticals, 8; Merck Sharp Dome, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 8; Roche Pharmaceuticals, 8 Schneeweiss, Sebastian, MD, ScD Session II: Methods for Comparative Effectiveness Research . . . . . . . . . . . . 22 Disclosure: Nothing to Disclose Schneider, Rayfel, MBBCh Systemic Arthritis and Still’s Disease. . . . . 51 Disclosure: Consultant, 5 Schrag, Deborah, MD, MPH Session III: Developing Standardized Treatment Algorithms for Registries . . . . . . . . . . . 22 Disclosure: Nothing to Disclose Schwab, Pascale, MD Practice Potpourri . . . . . . . . . . . . . . .106 Disclosure: Nothing to Disclose Schwartz, Lawrence B., MD, PhD Hereditary Angioedema . . . . . . . . . . .118 Disclosure: GSK: clinical trials, 2; Phadia: tryptase assay, 7 Seibold, James R., MD Pulmonary Hypertension in the Rheumatic Diseases . . . . . . . . . . . . . . . . . . . . 27 Disclosure: Actelion Pharmaceuticals US, 2; Apricus, 5; Celgene, 5; Fibrogen, 5; Genentech and Biogen IDEC Inc., 5; Sanofi-Aventis Pharmaceutical, 5; United Therapeutics, 2 Seo, Philip, MD, MHS Large Vessel Vasculitis 2011 . . . . . . . . . 22 Disclosure: Nothing to Disclose Serhan, Charles, PhD 2011 Hench Lecture: Resolution of Inflammation . . . . . . . . . . . . . . . . . 26 Disclosure: Bayer Health Care, 7; NIH, 2; Resolvyx Pharmaceutical Comany, 1 Seton, Margaret, MD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Seymour, Sally M., MD Update on Safety Issues in the Treatment of Rheumatic Diseases – From the FDA and Beyond . . . . . . . . . . . . . . . . . . . . . . . . .126 Disclosure: Nothing to Disclose Shadick, Nancy A., MD, MPH Rheumatoid Arthritis: Difficult Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . 27 Disclosure: Amgen Abbott, Genentech, Crescendo Biosciences, Biogen Idec, 2 334 2011 Program Book
Shah, Ami A., MD, MHS ACR Plenary Session I: Discovery 2011 . . . 31 Disclosure: Actelion Pharmaceuticals US, 2 Shakoor, Najia, MD Pain, the Brain, and Osteoarthritis. . . . . . 96 Disclosure: Nothing to Disclose The Neuromuscular System in Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . 29 Disclosure: Nothing to Disclose Shane, Elizabeth J., MD Session V: Therapeutic Targeting of Bone Disease . . . . . . . . . . . . . . . . . . . . . 21 Disclosure: Eli Lilly and Company, 2; Merck Pharmaceuticals, 2; Novartis Pharmaceutical Corporation, 2 Shanmugam, Victoria K., MBBS, MRCP Challenging Complications of Systemic Sclerosis . . . . . . . . . . . . . . . . . . . . . . . . .107 Disclosure: NIH, 2; Spouse is an attorney with Williams and Connolly LLP and represents various pharmaceutical companies. , 9 Did You Brush Your Teeth Today . . . . . . 62 Disclosure: NIH, 2; Spouse is an attorney with Williams and Connolly LLP and represents various pharmaceutical companies. , 9 Hereditary Angioedema . . . . . . . . . . .118 Disclosure: NIH, 2; Spouse is an attorney with Williams and Connolly LLP and represents various pharmaceutical companies. , 9 Sharif, Roozbeh, MD Plenary Session III . . . . . . . . . . . . . . . 91 Disclosure: Nothing to Disclose Sharma, Leena, MD Mechanical Factors in Knee Osteoarthritis: A Plausible Road to Riches . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Shepherd, Rebecca M., MD RAC and Roll – How to Perform Complex Chart Audits . . . . . . . . . . . . . . . . . . . . . 56 Disclosure: Nothing to Disclose Sherry, David D., MD Career Opportunities in Rheumatology: Making a Choice . . . . . . . . . . . . . . . . . . . .123 Disclosure: Nothing to Disclose Shore, Eileen M., PhD Session III: Mechanisms of De-Regulated Bone Remodeling in Rheumatic Diseases . . . . . 21 Disclosure: Nothing to Disclose Shubin, Neil H., PhD ACR/ARHP Opening Lecture and Awards . . 24 Disclosure: Nothing to Disclose Siemons, Liseth, MSc Improving Health Measurement in Rheumatology . . . . . . . . . . . . . . . . .115 Disclosure: Nothing to Disclose Sieper, Joachim, MD Ankylosing Spondylitis: Disease Modification . . . . . . . . . . . . . . . . . . . . . . . . . 86 Disclosure: Abbott Immunology Pharmaceuticals, 8; BMS, 2; Lilly, 5; Merck Pharmaceuticals, 8; Pfizer Inc, 8; Roche Pharmaceuticals, 8; UCB, 8 Silverman, Gregg J., MD Apoptosis, Phagocytic Clearance and Autoimmune and Inflammatory Diseases . .116 Disclosure: Have consulted for Genentech, Roche and Biogen Idec, 5; Wife is employed by Gilead., 3 Complimentary Roles for Complement in the Rheumatic Diseases . . . . . . . . . . . . . . 85 Disclosure: Have consulted for Genentech, Roche and Biogen Idec, 5; Wife is employed by Gilead., 3 Genetic Defects, AIRE and Autoimmunity. . 88 Disclosure: Have consulted for Genentech, Roche and Biogen Idec, 5; Wife is employed by Gilead., 3 Debate: Joints for Joints: Medical Marijuana is Useful for Treating Rheumatic Disease . . . 72 Disclosure: Nothing to Disclose Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm . . . . . . . . . . . . . . . . . . . . . . . 27, 59 Disclosure: Amgen, Genentech, Lilly, Novartis, Pfizer / Wyeth, Roche Pharmaceuticals, Roche Diagnostics, Warner Chilcott, 5; Amgen, Lilly, Novartis, Pfizer / Wyeth, Roche Pharmaceuticals, 8; Cedars-Sinai Medical Center , 3; Lilly, Pfizer / Wyeth, Warner Chilcott, 2 Simkin, Peter A., MD Rheumatic Disease Update: Calcium Pyrophosphate Crystal Deposition Disease . 31 Disclosure: Nothing to Disclose Simopoulos, Artemis P., MD Omega-3 Fatty Acids in Inflammation and Cardiovascular Health. . . . . . . . . . . . . 85 Disclosure: Nothing to Disclose Singh, Jasvinder, MD, MPH 2011 Updated ACR Rheumatoid Arthritis Guidelines . . . . . . . . . . . . . . . . . . . 63 Disclosure: Takeda, Novartis, Savient, URL, 5; Omeract, 6; Takeda, Savient, 2; University of Alabama and Birmingham Veterans Affairs Medical Center, 3 Heart Disease and Rheumatoid Arthritis . . 73 Disclosure: Takeda, Novartis, Savient, URL, 5; Omeract, 6; Takeda, Savient, 2; University of Alabama and Birmingham Veterans Affairs Medical Center, 3 The Neuromuscular System in Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 Disclosure: Takeda, Novartis, Savient, URL, 5; Omeract, 6; Takeda, Savient, 2; University of Alabama and Birmingham Veterans Affairs Medical Center, 3 Skea, Warren, PhD CORC Forum: Payment Reform Options . . . 92 Disclosure: Nothing to Disclose Slusher, Barbara A., PA-C, MSW Highlights from the 2011 ARHP Sessions . .117 Disclosure: Nothing to Disclose Solomon, Daniel H., MD, MPH Introduction of Afternoon Session . . . . . . 22 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Rheumatoid Arthritis: Safety of Novel Therapies . . . . . . . . . . . . . . . . . . . . . . . . . 62 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Session I: Introduction and Overview of Comparative Effectiveness Research from the Perspective of Government and Insurers . . 21 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Session II: Methods for Comparative Effectiveness Research . . . . . . . . . . . . 22 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Welcome and Introductions . . . . . . . . . 21 Disclosure: Abbott Immunology Pharmaceuticals, 2; Amgen, 2; Corrona, 5; Pfizer Inc, 9 Somers, Emily C., PhD, ScM Theories on Sex Disparities in Autoimmune Disease: From Estrogen to the X Chromosome . . . . . . . . . . . . . . . . . . . . . . . . . 84 Disclosure: Nothing to Disclose Spiera, Robert F., MD Curbside Consults - Ask the Professors . . . 59 Disclosure: Novartis Pharmaceutical Corporation, United Therapeutics, BMS, 2 Difficult Raynaud’s Phenomena . . . . . . . 33 Disclosure: Novartis Pharmaceutical Corporation, United Therapeutics, BMS, 2 Thieves’ Market: Show Me Your Best Cases. 71 Disclosure: Novartis Pharmaceutical Corporation, United Therapeutics, BMS, 2 Vasculitis: Key Issues for the Clinician in Three Unique Diseases . . . . . . . . . . . . . . . . 96 Disclosure: Roche Pharmaceuticals/Genetech, 5 Spindler, Kurt P., MD ACR REF Marshall J. Schiff, MD, Memorial Lectureship: Multicenter Orthopaedic Outcomes Network - A Prospective Longitudinal Cohort of ACL Reconstruction Outcomes . . . . . . . . 82 Disclosure: Nothing to Disclose St.Clair, E. William, MD ACR Leadership Town Hall Meeting . . . . . 95 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2 ACR Plenary Session I: Discovery 2011 . . . 30 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2 ACR REF Paul Klemperer, MD Memorial Lectureship: Osteoarthritis - Quo Vadis - Where are We Now - Where are We Going . . . . 89 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2 Extra Glandular Manifestations of Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . .107 Disclosure: Genentech and Biogen IDEC Inc., 2; Medimmune, 2 Invited Speaker /Moderator Index 2011 Program Book 335
Page 1 and 2:
program B O O K Pre-Conference Cour
Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
Page 5 and 6:
TABLE OF CONTENTS POLICIES Copyrigh
Page 7 and 8:
TABLE OF CONTENTS ACR Immunology Up
Page 9 and 10:
TABLE OF CONTENTS Vasculitis Poster
Page 11 and 12:
However, the ACR continues to requi
Page 13 and 14:
MEETING NAVIGATION GUIDE To navigat
Page 15 and 16:
Newsroom Located in room W175c, use
Page 17:
Guided Poster Tours Guided poster t
Page 20 and 21:
FRIDAY November 4, 2011 9:15 am Ult
Page 22 and 23:
SATURDAY, NOVEMBER 5, 2011 12:00 -
Page 24 and 25:
SATURDAY November 5, 2011 8:35 am T
Page 26 and 27:
SATURDAY November 5, 2011 Pain: Pat
Page 28 and 29:
SUNDAY November 6, 2011 SUNDAY, NOV
Page 30 and 31:
SUNDAY November 6, 2011 Upon comple
Page 32 and 33:
EXHIBITS 10:00 am - 5:00 pm INNOVAT
Page 34 and 35:
SUNDAY November 6, 2011 ARHP SPECIA
Page 36 and 37:
SUNDAY November 6, 2011 W179b Rheum
Page 38 and 39:
3:15 pm 732. Notch Signaling Pathwa
Page 40 and 41:
SUNDAY November 6, 2011 3:15 pm 756
Page 42 and 43:
SUNDAY November 6, 2011 Children’
Page 44 and 45:
Page 46 and 47:
3:30 pm Demonstration and Practice
Page 48 and 49:
Yasser M. El Miedany 1 , Maha El Ga
Page 50 and 51:
SUNDAY November 6, 2011 48 Musculos
Page 52 and 53:
Page 54 and 55:
SUNDAY November 6, 2011 52 4:55 pm
Page 56 and 57:
MONDAY, NOVEMBER 7, 2011 ACR/ARHP R
Page 58 and 59:
MONDAY November 7, 2011 W185a Scler
Page 60 and 61:
MONDAY November 7, 2011 Upon comple
Page 62 and 63:
Upon completion of this session, pa
Page 64 and 65:
MONDAY November 7, 2011 W187b Basic
Page 66 and 67:
MONDAY November 7, 2011 2:30 pm Cel
Page 68 and 69:
MONDAY November 7, 2011 Indianapoli
Page 70 and 71:
3:45 pm 1628. Association of Knee P
Page 72 and 73:
MONDAY November 7, 2011 Glostrup, C
Page 74 and 75:
MONDAY November 7, 2011 3:33 pm A R
Page 76 and 77:
MONDAY November 7, 2011 4:30 pm Ris
Page 78 and 79:
Institutet, Stockholm, Sweden, 6 Un
Page 80 and 81:
5:45 pm 1700. Successful Dose De-Es
Page 82 and 83:
MONDAY November 7, 2011 Michigan, A
Page 84 and 85:
MONDAY November 7, 2011 4:45 pm 172
Page 86 and 87:
MONDAY November 7, 2011 5:25 pm Imp
Page 88 and 89:
TUESDAY November 8, 2011 ARHP CONCU
Page 90 and 91:
TUESDAY November 8, 2011 9:25 am Is
Page 92 and 93:
ACR PRACTICE ISSUE 9:30 - 10:30 am
Page 94 and 95:
TUESDAY November 8, 2011 noon 2431.
Page 96 and 97:
TUESDAY November 8, 2011 W186b Vasc
Page 98 and 99:
ACR CLINICAL SYMPOSIA 2:30 - 4:00 p
Page 100 and 101:
TUESDAY November 8, 2011 3:45 pm 24
Page 102 and 103:
TUESDAY November 8, 2011 University
Page 104 and 105:
TUESDAY November 8, 2011 and Oncolo
Page 106 and 107:
Italy, 3 Hospital Universitario La
Page 108 and 109:
3:10 pm Case Study Diane V. Lacaill
Page 110 and 111:
• discuss the evidence to support
Page 112 and 113:
TUESDAY November 8, 2011 4:45 pm 25
Page 114 and 115:
5:15 pm 2532. Selection of Patients
Page 116 and 117:
TUESDAY November 8, 2011 ACR/ARHP C
Page 118 and 119:
WEDNESDAY, NOVEMBER 9, 2011 ACR/ARH
Page 120 and 121:
9:00 am Mechanisms of Thrombosis in
Page 122 and 123:
WEDNESDAY November 9, 2011 A. Kopec
Page 124 and 125:
WEDNESDAY November 9, 2011 9:15 am
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
WEDNESDAY November 9, 2011 Graduate
Page 132 and 133:
11:00 am The Process: Defining Appr
Page 134 and 135:
ACR Poster Session A 11. Myocardial
Page 136 and 137:
ACR Poster Session A 37. Regulation
Page 138 and 139:
ACR Poster Session A 64. Interleuki
Page 140 and 141:
ACR Poster Session A Mexico City, M
Page 142 and 143:
ACR Poster Session A 121. An Analys
Page 144 and 145:
ACR Poster Session A 146. National
Page 146 and 147:
ACR Poster Session A 165. Genome-Wi
Page 148 and 149:
ACR Poster Session A 185. US Examin
Page 150 and 151:
ACR Poster Session A Jones 1 , Andr
Page 152 and 153:
ACR Poster Session A Gerald J. D. H
Page 154 and 155:
ACR Poster Session A 258. Etanercep
Page 156 and 157:
ACR Poster Session A GA, 6 Hospital
Page 158 and 159:
ACR Poster Session A 305. Pathway-B
Page 160 and 161:
ACR Poster Session A 328. Near Miss
Page 162 and 163:
ACR Poster Session A 351. A Novel M
Page 164 and 165:
ACR Poster Session A Sugihara 6 , K
Page 166 and 167:
ACR Poster Session A 398. Rituximab
Page 168 and 169:
ACR Poster Session A & Johnson Phar
Page 170 and 171:
ACR Poster Session A 436. Predicted
Page 172 and 173:
ACR Poster Session A Tomomi Tsuru 1
Page 174 and 175:
ACR Poster Session A 479. Follow up
Page 176 and 177:
ACR Poster Session A 496. A Chimeri
Page 178 and 179:
ACR Poster Session A 518. Associati
Page 180 and 181:
ACR Poster Session A Piestany, Slov
Page 182 and 183:
ACR Poster Session A 576. Fn14 Defi
Page 184 and 185:
ACR Poster Session A 593. Plasma Le
Page 186 and 187:
ACR Poster Session A 611. Why Do Lu
Page 188 and 189:
ACR Poster Session A 634. Associati
Page 190 and 191:
ACR Poster Session A Alarcon-Riquel
Page 192 and 193:
ACR Poster Session A Laboratories,
Page 194 and 195:
ACR Poster Session A Movsisyan, Lid
Page 196 and 197:
ACR Poster Session A Th1 Cells Expa
Page 198 and 199:
ACR/ARHP Poster Session B College o
Page 200 and 201:
ACR/ARHP Poster Session B 920. Econ
Page 202 and 203:
ACR/ARHP Poster Session B Study. A.
Page 204 and 205:
ACR/ARHP Poster Session B 974. Dise
Page 206 and 207:
ACR/ARHP Poster Session B 1001. Mic
Page 208 and 209:
ACR/ARHP Poster Session B 206 Khann
Page 210 and 211:
ACR/ARHP Poster Session B 208 Pulmo
Page 212 and 213:
ACR/ARHP Poster Session B Swearinge
Page 214 and 215:
ACR/ARHP Poster Session B 212 Felds
Page 216 and 217:
ACR/ARHP Poster Session B 214 Corbi
Page 218 and 219:
ACR/ARHP Poster Session B 1161. End
Page 220 and 221:
ACR/ARHP Poster Session B 1182. Uri
Page 222 and 223:
ACR/ARHP Poster Session B 1205. A S
Page 224 and 225:
ACR/ARHP Poster Session B 222 Murth
Page 226 and 227:
ACR/ARHP Poster Session B San Diego
Page 228 and 229:
ACR/ARHP Poster Session B 1266. Eva
Page 230 and 231:
ACR/ARHP Poster Session B 1296. Pat
Page 232 and 233:
ACR/ARHP Poster Session B 230 1320.
Page 234 and 235:
ACR/ARHP Poster Session B 1348. Syn
Page 236 and 237:
ACR/ARHP Poster Session B 1375. Ant
Page 238 and 239:
ACR/ARHP Poster Session B 1398. Cli
Page 240 and 241:
ACR/ARHP Poster Session B Baltimore
Page 242 and 243:
ACR/ARHP Poster Session B 1451. Ele
Page 244 and 245:
ACR/ARHP Poster Session B Sclerosis
Page 246 and 247:
ACR/ARHP Poster Session B 1496. Evi
Page 248 and 249:
ACR/ARHP Poster Session B 1518. Pro
Page 250 and 251:
ACR/ARHP Poster Session B Hagen 1 ,
Page 252 and 253:
ACR/ARHP Poster Session B ARHP Clin
Page 254 and 255:
ACR/ARHP Poster Session C Karl Eger
Page 256 and 257:
ACR/ARHP Poster Session C Tampere S
Page 258 and 259:
ACR/ARHP Poster Session C 256 1 Jun
Page 260 and 261:
ACR/ARHP Poster Session C Universit
Page 262 and 263:
ACR/ARHP Poster Session C 1864. Epi
Page 264 and 265:
ACR/ARHP Poster Session C 262 Hospi
Page 266 and 267:
ACR/ARHP Poster Session C 2 Biogen
Page 268 and 269:
ACR/ARHP Poster Session C 1945. Cir
Page 270 and 271:
ACR/ARHP Poster Session C 268 1974.
Page 272 and 273:
ACR/ARHP Poster Session C 2003. Eff
Page 274 and 275:
ACR/ARHP Poster Session C Hosp Gast
Page 276 and 277:
ACR/ARHP Poster Session C Toronto,
Page 278 and 279:
ACR/ARHP Poster Session C Francisco
Page 280 and 281:
ACR/ARHP Poster Session C 2105. Inc
Page 282 and 283:
ACR/ARHP Poster Session C Universit
Page 284 and 285:
ACR/ARHP Poster Session C 282 2151.
Page 286 and 287: ACR/ARHP Poster Session C 284 2175.
Page 288 and 289: ACR/ARHP Poster Session C 286 2196.
Page 290 and 291: ACR/ARHP Poster Session C 2217. Lon
Page 292 and 293: ACR/ARHP Poster Session C Research
Page 294 and 295: ACR/ARHP Poster Session C 2258. sIL
Page 296 and 297: ACR/ARHP Poster Session C 2290. The
Page 298 and 299: ACR/ARHP Poster Session C Universit
Page 300 and 301: ACR/ARHP Poster Session C 2345. IL-
Page 302 and 303: ACR/ARHP Poster Session C 2376. Gra
Page 304 and 305: ACR/ARHP Poster Session C 2399. Spe
Page 306 and 307: REF Industry Roundtable-supported S
Page 308 and 309: REF Industry Roundtable-supported S
Page 310 and 311: Industry-supported POST-CONFERENCE
Page 312 and 313: CERTIFICATES OF CME CREDIT OR PARTI
Page 314 and 315: 2011 ACR/ARHP Annual Meeting Leader
Page 316 and 317: 2011 ACR/ARHP Annual Meeting Leader
Page 318 and 319: EXHIBITORS Abbott Pharmaceuticals B
Page 320 and 321: EXHIBITORS Lippincott, Williams and
Page 322 and 323: acknowledgements The ACR, the ARHP
Page 324 and 325: Invited Speaker /Moderator Index 32
Page 328 and 329: Invited Speaker /Moderator Index Ev
Page 334 and 335: Invited Speaker /Moderator Index Mu
Page 338 and 339: Invited Speaker /Moderator Index St
Page 340 and 341: Invited Speaker /Moderator Index Wi
Page 342 and 343: aBSTRACT author Index 340 Alpers, C
Page 344 and 345: aBSTRACT author Index Bawa, WA 259
Page 346 and 347: aBSTRACT author Index 344 Broder, A
Page 348 and 349: aBSTRACT author Index 346 Chaves, L
Page 350 and 351: aBSTRACT author Index 348 Dalbeth,
Page 352 and 353: aBSTRACT author Index Eastman, PS 3
Page 354 and 355: aBSTRACT author Index 352 Fragoso-L
Page 356 and 357: aBSTRACT author Index Gordon, C 4,
Page 358 and 359: aBSTRACT author Index Hemmati, I 13
Page 360 and 361: aBSTRACT author Index 358 Ishigatsu
Page 362 and 363: aBSTRACT author Index 360 Keeling,
Page 364 and 365: aBSTRACT author Index 362 Kumar, V
Page 366 and 367: aBSTRACT author Index 364 Lim, M 13
Page 368 and 369: aBSTRACT author Index 366 Marshall,
Page 370 and 371: aBSTRACT author Index 368 MMF/AZA L
Page 372 and 373: aBSTRACT author Index 370 Noel, D 1
Page 374 and 375: aBSTRACT author Index 372 Pawlita,
Page 376 and 377: aBSTRACT author Index 374 Ramos, I
Page 378 and 379: aBSTRACT author Index 376 Rönnblom
Page 380 and 381: aBSTRACT author Index 378 Shaykevic
Page 382 and 383: aBSTRACT author Index Su, J 22, 139
Page 384 and 385: aBSTRACT author Index 382 Tomcik, M
Page 386 and 387:
aBSTRACT author Index 384 Villeneuv
Page 388 and 389:
aBSTRACT author Index 386 Wu, X 650
Page 390 and 391:
abstract keyword Index 388 18FDG PE
Page 392 and 393:
abstract keyword Index 2092, 2113,
Page 394 and 395:
abstract keyword Index 392 macropha
Page 396 and 397:
abstract keyword Index 387, 388, 38
Page 398 and 399:
Abstract Moderator disclosure A Ano
Page 400 and 401:
Abstract Moderator disclosure Jonas
Page 402 and 403:
V van der Heijde, Desiree, MD, PhD
Page 404 and 405:
Notes 402 2011 Program Book
Page 406 and 407:
immunosuppressive agents is not rec
Page 408:
In appropriate patients with psoria
show all

Program Book - Confex

Create successful ePaper yourself

Delete template?

Save as template?